* Written informed consent from parent or guardian if applicable (age\<18 years)
For HIV-infected subjects:
* HIV-positive
* Asymptomatic subjects (generalized lymphadenopathy is accepted)
* Lymphocyte CD4+ count \> or equal to 350 cells/mm3
For subjects receiving HAART:
* Good compliance to therapy
* At least two suppressed viral loads HIV-RNA (\<37copies/ml9 during 6 months prior to enrollment.
You may not be if
For female subjects (both HIV-infected and healthy)
Pregnancy or breastfeeding
Total hysterectomy. Participants who have undergone partial hysterectomy and have a cervix are not excluded.
For both females and males (HIV-infected and healthy):
Prior vaccination with quadrivalent HPV vaccine Gardasil before study entry.
History of severe allergic reaction after previous vaccination or hypersensitivity to any vaccine component.
Any serious chronic or progressive disease (other than HIV) according to the judgment of the investigator:
Acute infection requiring therapy or fever at time of enrollment
Chronic autoimmune or oncologic disease receiving chemotherapy
Concomitant therapies (other than HAART):
Chronic therapy (for more than 14 days consecutively) with immunosuppressive or immunomodulating agents or chemotherapy during the 6 months prior to study entry.
Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation prior to study entry.
Use of investigational agents within 4 weeks prior to study enrollment.
Current drug or alcohol use or dependence.
Documented history of non-adherence to antiretroviral treatment regimen within 12 months prior to study entry.
